Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Transitional Cell × apatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Stomach Neoplasms 54 Carcinoma, Hepatocellular 39 Carcinoma, Non-Small-Cell Lung 21 Small Cell Lung Carcinoma 18 Ovarian Neoplasms 17 Colorectal Neoplasms 15 Breast Neoplasms 13 Sarcoma 12 Triple Negative Breast Neoplasms 11 Nasopharyngeal Carcinoma 11 Neoplasms 10 Esophageal Squamous Cell Carcinoma 10 Esophageal Neoplasms 9 Cholangiocarcinoma 9 Neoplasm Metastasis 7 Lung Neoplasms 7 Advanced Gastric Cancer 7 Squamous Cell Carcinoma of Head and Neck 6 Recurrence 6 Osteosarcoma 6 Head and Neck Neoplasms 6 Biliary Tract Neoplasms 6 Uterine Cervical Neoplasms 5 Liver Neoplasms 5 Solid Tumor 4 Pancreatic Neoplasms 4 Melanoma 4 Glioma 4 Thyroid Neoplasms 3 NSCLC 3

Interventions

pembrolizumab 70 Gemcitabine 44 Nivolumab 36 Cisplatin 32 atezolizumab 31 Carboplatin 25 avelumab 24 enfortumab vedotin 21 Docetaxel 20 Magnetic Resonance Spectroscopy 16 Mitomycin 14 Ipilimumab 14 Paclitaxel 13 Specimen Handling 11 durvalumab 10 toripalimab 8 sacituzumab govitecan 8 vinflunine 7 cabozantinib 7 Pemetrexed 7 Injections 6 Cyclophosphamide 6 Bevacizumab 6 tislelizumab 5 pemigatinib 5 Taxes 5 Fluorodeoxyglucose F18 5 Biopsy 5 lenvatinib 4 fludarabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03407976 2020-07-15

APPEASE

University of Utah

Phase 1 Terminated

Adenocarcinoma, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡